Article
Transplantation
Rachel Hellemans, Daniel Abramowicz
Summary: CMV-related complications after kidney transplantation present a significant challenge. Tailoring preventive strategies based on individual patient risk levels can improve outcomes. CMV-specific T-cell assays can help predict CMV risk pre-transplantation. Immunosuppressive regimens including mammalian target of rapamycin inhibitors can reduce CMV risk. New antiviral agents and adoptive T-cell therapy hold promise for future treatment options.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Infectious Diseases
Jorge Andrade-Sierra, Alejandro Heredia-Pimentel, Enrique Rojas-Campos, Diana Ramirez Flores, Jose Cerrillos-Gutierrez, Alejandra G. Miranda-Diaz, Luis A. Evangelista-Carrillo, Petra Martinez-Martinez, Basilio Jalomo-Martinez, Eduardo Gonzalez-Espinoza, Benjamin Gomez-Navarro, Miguel Medina-Perez, Juan Jose Nieves-Hernandez
Summary: In renal transplant recipients, low doses of ATG may increase the risk of developing CMV, while the use of basiliximab may be more favorable. Additionally, factors such as lack of prophylaxis, ATG use, tacrolimus toxicity, and lymphocyte count at the sixth month post-transplantation are associated with the risk of CMV.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Surgery
Maura L. L. Kreiser, Robert Dupuis, Kristen R. R. Szempruch, Laura M. M. Chargualaf
Summary: This study compared the efficacy of different doses of valganciclovir prophylaxis in liver transplant recipients and found no significant difference between the reduced dose and full dose groups in terms of incidence of CMV infection, neutropenia, or leukopenia, although the time to diagnosis of CMV was different.
CLINICAL TRANSPLANTATION
(2023)
Article
Hematology
Po-Hsien Li, Cheng-Hsien Lin, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu, Chieh-Lin Jerry Teng
Summary: The study suggests that low-dose valganciclovir prophylaxis may be an effective strategy to prevent CMV infection in patients undergoing allo-HSCT, particularly in resource-limited countries.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Immunology
Kjersti B. Blom, Grete K. Birkeland, Karsten Midtvedt, Trond G. Jenssen, Anna V. Reisaeter, Halvor Rollag, Anders Hartmann, Solbjorg Sagedal, Ivar Sjaastad, Garth Tylden, Gro Njolstad, Einar Nilsen, Andreas Christensen, Anders Asberg, Jon A. Birkeland
Summary: This study compares the long-term outcomes of prophylactic and preemptive CMV preventive strategies in kidney transplant recipients. The study found that there were no significant differences in long-term outcomes such as patient death and graft loss between the two strategies in D+/R- kidney transplant recipients.
Article
Immunology
Danielle Ecabert, Christine Pham, Brett J. Pierce, William L. Musick, Duc T. Nguyen, Edward A. Graviss
Summary: In non-kidney transplant recipients, the study found that valganciclovir 450 mg three times weekly post-HD had similar rates of leukopenia, neutropenia, thrombocytopenia, and CMV infection compared to valganciclovir dosed per renal function.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Urology & Nephrology
Louis Maniere, Johan Noble, Florian Terrec, Hamza Naciri Bennani, Eloi Chevallier, Benedicte Janbon, Raphaele Germi, Mathilde Bugnazet, Farida Imerzoukene, Paolo Malvezzi, Lionel Rostaing, Thomas Jouve
Summary: The study found that administering everolimus plus low-dose tacrolimus to de novo kidney-transplant recipients was associated with low rates of CMV disease, especially in R+ patients without CMV prophylaxis.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2021)
Article
Immunology
Andrew S. Jarrell, Jessica R. Crow, Sara E. Strout, Rachel M. Kruer, Lindsey P. Toman, Maria Dioverti-Prono, Laura Lees, Robin K. Avery, Mark A. Marzinke
Summary: Valganciclovir 450 mg enterally every 24 hours achieved ganciclovir trough concentrations >= 0.60 mu g/mL in most patients on CVVHD, similar to those reported with intravenous ganciclovir for prophylaxis in this population. Neutropenia did not occur in the study period. Thrombocytopenia was common and likely multifactorial.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Pharmacology & Pharmacy
Shannon A. Ross, David Kimberlin
Summary: cCMV infection is a major cause of hearing loss and neurological disabilities in children globally. Most infants with cCMV are asymptomatic at birth, but 10-15% will develop hearing loss. Diagnosis relies on detecting the virus from urine or saliva within the first three weeks of life, with saliva PCR being the preferred method. Prevention strategies are limited, and antiviral therapy is standard for infants with symptomatic cCMV.
ANTIVIRAL RESEARCH
(2021)
Article
Urology & Nephrology
Takaya Iida, Kenichiro Miura, Hideki Ban, Taro Ando, Yoko Shirai, Sho Ishiwa, Atsutoshi Shiratori, Naoto Kaneko, Tomoo Yabuuchi, Kiyonobu Ishizuka, Masanori Takaiwa, Kazuhide Suyama, Masataka Hisano, Motoshi Hattori
Summary: This study analyzed high-risk pediatric patients who received oral VGCV prophylaxis at Tokyo Women's Medical University from August 2018 to March 2019. Results showed that all patients received a dose of 450 mg, but most required dose reduction or discontinuation due to adverse events, and all patients developed late-onset CMV disease with no seroconversion observed during prophylaxis. Further studies are needed to investigate the safety and efficacy of VGCV prophylaxis in Japanese pediatric recipients.
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2021)
Article
Multidisciplinary Sciences
Monica Rika Nakamura, Lucio R. Requiao-Moura, Roberto Mayer Gallo, Camila Botelho, Julia Taddeo, Laila Almeida Viana, Claudia Rosso Felipe, Jose Medina-Pestana, Helio Tedesco-Silva
Summary: The study compares the effectiveness of preemptive treatment for cytomegalovirus (CMV) infection after kidney transplant using antigenemia and RT-PCR testing. It finds that both methods yield similar results in preventing CMV disease and related events. Acute rejection and glomerular filtration rate are identified as risk factors for CMV disease.
SCIENTIFIC REPORTS
(2022)
Article
Infectious Diseases
Yuka Torii, Ichiro Morioka, Yasumasa Kakei, Kazumichi Fujioka, Yu Kakimoto, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Akira Oka, Yoshinori Ito
Summary: This study aimed to compare the accuracy of quantification methods for cytomegalovirus (CMV) infection using whole blood and plasma, and explored the relationship between CMV DNA levels and VGCV therapy. The results showed that plasma CMV viral loads were significantly decreased at the end of therapy, and overall, using plasma to measure CMV viral loads is a feasible approach to monitor the efficacy of CMV infection in children.
BMC INFECTIOUS DISEASES
(2023)
Article
Ophthalmology
Matthias Lenglinger, Therese Schick, Dominika Pohlmann, Uwe Pleyer
Summary: This study reports objective morphologic changes in Cytomegalovirus (CMV)-positive Posner-Schlossman syndrome (PSS), showing a correlation between retinal nerve fiber layer (RNFL) thinning, corneal endothelial cell (CEC) loss, and the disease. Elevated intraocular pressures pose a significant challenge. OCT scans and endothelial microscopy may provide guidance for treatment decisions.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Urology & Nephrology
Tomas Reischig, Tomas Vlas, Martin Kacer, Kristyna Pivovarcikova, Daniel Lysak, Jana Nemcova, Petr Drenko, Jana Machova, Mirko Bouda, Monika Sedivcova, Stanislav Kormunda
Summary: This study compared the efficacy of valganciclovir prophylaxis and preemptive therapy in preventing CMV infection in kidney transplant recipients. The results showed that both regimens had similar effectiveness in preventing CMV disease, but preemptive therapy had a higher incidence of CMV DNAemia.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Pediatrics
Iona Madden, Veronique Baudouin, Marina Charbit, Bruno Ranchin, Gwenaelle Roussey, Robert Novo, Florentine Garaix, Stephane Decramer, Marc Fila, Elodie Merieau, Isabelle Vrillon, Ariane Zaloszyc, Julien Hogan, Jerome Harambat
Summary: This survey assessed the current CMV prevention and treatment strategies used among French pediatric kidney transplantation centers and found variations and inconsistencies in CMV management.
FRONTIERS IN PEDIATRICS
(2022)
